Fenofibrate and dipyridamole treatments in low-doses either alone or in combination blunted the development of nephropathy in diabetic rats.

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Pharmacological Research

• Publication date

  2014-12-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/j.phrs.2014.08.008PMID 25263930
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Low Protein Diet Inhibits Uric Acid Synthesis and Attenuates Renal Damage in Streptozotocin-Induced Diabetic Rats

  2014cited by this paper
• Classical and pleiotropic actions of dipyridamole: Not enough light to illuminate the dark tunnel?

  2014cited by this paper
• Low-dose dipyridamole treatment partially prevents diabetes mellitus-induced vascular endothelial and renal abnormalities in rats.

  2014cited by this paper
• Altered renal lipid metabolism and renal lipid accumulation in human diabetic nephropathy

  2014cited by this paper
• Association of serum uric acid with proteinuria in type 2 diabetic patients

  2013cited by this paper
• Differential effects of low-dose fenofibrate treatment in diabetic rats with early onset nephropathy and established nephropathy.

  2013cited by this paper
• Are PPAR alpha agonists a rational therapeutic strategy for preventing abnormalities of the diabetic kidney?

  2012cited by this paper
• Treatment with dipyridamole improves cardiac function and prevent injury in a rat model of hemorrhage.

  2012cited by this paper
• The PPAR Alpha gene is associated with triglyceride, low-density cholesterol, and inflammation marker response to fenofibrate intervention: The GOLDN Study

  2012cited by this paper
• Fibrates: therapeutic potential for diabetic nephropathy?

  2012cited by this paper
• The combined strategy with PPARα agonism and AT₁ receptor antagonism is not superior relative to their individual treatment approach in preventing the induction of nephropathy in the diabetic rat.

  2012cited by this paper
• Exacerbation of diabetic nephropathy by hyperlipidaemia is mediated by Toll-like receptor 4 in mice

  2012cited by this paper
• Telmisartan in the management of diabetic nephropathy: a contemporary view.

  2012cited by this paper
• Antiplatelet Therapy for Transient Ischemic Attack

  2012cited by this paper
• Association between red blood cell distribution width and macrovascular and microvascular complications in diabetes

  2011cited by this paper
• Uric acid as a mediator of diabetic nephropathy.

  2011cited by this paper
• Role of Peroxisome Proliferator-Activated Receptor α in Diabetic Nephropathy

  2011cited by this paper
• Serum uric acid as a new player in the development of diabetic nephropathy.

  2011cited by this paper
• Fenofibrate attenuates tubulointerstitial fibrosis and inflammation through suppression of nuclear factor-κB and transforming growth factor-β1/Smad3 in diabetic nephropathy

  2010cited by this paper
• The low dose combination of fenofibrate and rosiglitazone halts the progression of diabetes-induced experimental nephropathy.

  2010cited by this paper
• Reversibility of renal injury with cholesterol lowering in hyperlipidemic diabetic mice1

  2010cited by this paper
• Effect of fenofibrate on uric acid metabolism and urate transporter 1.

  2010cited by this paper
• Emerging role of PPAR ligands in the management of diabetic nephropathy.

  2009cited by this paper
• Serum Uric Acid as a Predictor for Development of Diabetic Nephropathy in Type 1 Diabetes

  2009cited by this paper
• Pathophysiology of Diabetic Nephropathy: Involvement of Multifaceted Signalling Mechanism

  2009cited by this paper
• Antidiabetic properties of S-allyl cysteine, a garlic component on streptozotocin-induced diabetes in rats

  2009cited by this paper
• Recent advances in pharmacotherapy for diabetic nephropathy: current perspectives and future directions.

  2009cited by this paper
• Fibrates and microvascular complications in diabetes--insight from the FIELD study.

  2009cited by this paper
• Elevated serum creatinine levels associated with fenofibrate therapy.

  2008cited by this paper
• Diabetic Nephropathy: Mechanisms of Renal Disease Progression

  2008cited by this paper
• Ameliorative effect of combination of benfotiamine and fenofibrate in diabetes-induced vascular endothelial dysfunction and nephropathy in the rat

  2008cited by this paper
• Enhanced cardioprotection against ischemia-reperfusion injury with a dipyridamole and low-dose atorvastatin combination.

  2007cited by this paper
• Renoprotection by Telmisartan versus Benazepril in Streptozotocin Induced Diabetic Nephropathy

  2006cited by this paper
• PPARalpha agonist fenofibrate improves diabetic nephropathy in db/db mice.

  2006cited by this paper
• Mechanism of dipyridamole's action in inhibition of venous and arterial smooth muscle cell proliferation.

  2006cited by this paper
• PPARα agonist fenofibrate improves diabetic nephropathy in db/db mice. Commentary

  2006cited by this paper
• Effect of Fenofibrate in Combination with Urate Lowering Agents in Patients with Gout

  2006cited by this paper
• The prevention of diabetic microvascular complications of diabetes: is there a role for lipid lowering?

  2005cited by this paper
• Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: results from the Diabetes Atherosclerosis Intervention Study (DAIS).

  2005cited by this paper
• Emerging Trends for Prevention and Treatment of Diabetic Nephropathy

  2004cited by this paper
• Antioxidant properties of dipyridamole as assessed by chemiluminescence.

  2003cited by this paper
• Oxidative stress in streptozotocin-induced diabetic rats: effects of garlic oil and melatonin.

  2003cited by this paper
• A Comparative Randomized and Placebo-controlled Short-term Trial of Aspirin and Dipyridamole for Overt Type-2 Diabetic Nephropathy

  2002cited by this paper
• Fenofibrate Increases Creatininemia by Increasing Metabolic Production of Creatinine

  2002cited by this paper
• Fibrate treatment can increase serum creatinine levels.

  2001cited by this paper
• The mechanism of alloxan and streptozotocin action in B cells of the rat pancreas.

  2001cited by this paper
• Fibrate treatment can increase serum creatinine levels

  2001cited by this paper
• [Fenofibrate increases blood creatinine, but does not change the glomerular filtration rate in patients with mild renal insufficiency].

  1999cited by this paper
• ACE Inhibitor Use Is Associated With Hospitalization for Severe Hypoglycemia in Patients With Diabetes

  1997cited by this paper
• Dipyridamole prevents diabetes-induced alterations of kidney function in rats

  1994cited by this paper
• Dipyridamole reduces urinary albumin excretion in diabetic patients with normo- or microalbuminuria.

  1990cited by this paper
• Administration of aspirin-dipyridamole reduces proteinuria in diabetic nephropathy.

  1989cited by this paper
• Blood urea nitrogen and creatinine.

  1986cited by this paper
• Blood urea nitrogen and creatinine.

  1986cited by this paper
• Conditions for "coronary steal" caused by coronary vasodilator in man.

  1982cited by this paper
• Conditions for Vasodilator-induced Coronary Steal in Experimental Myocardial Ischemia

  1978cited by this paper

• Differential Pre- and Post-Treatment Effects of Low-Dose Antidyslipidemic Drugs on Gentamicin-Induced Acute Nephrotoxicity in the Rat: A Histopathological and Biochemical Study.

  2025cites this paper
• The effects of simvastatin and fenofibrate on malondialdehyde and reduced glutathione concentrations in the plasma, liver, and brain of normolipidaemic and hyperlipidaemic rats

  2023cites this paper
• Green Synthesis, Characterizations of Zinc Oxide Nanoparticles from Aqueous Leaf Extract of Tridax procumbens Linn. and Assessment of their Anti-Hyperglycemic Activity in Streptozoticin-Induced Diabetic Rats

  2022cites this paper
• Dipyridamole ameliorates doxorubicin-induced cardiotoxicity

  2022cites this paper
• Fenofibrate, a PPARα agonist, reduces hepatic fat accumulation through the upregulation of TFEB-mediated lipophagy.

  2021cites this paper
• Diagnostics and treatment of chronic cerebral ischemia

  2020cites this paper
• Involvement of Peroxisome Proliferator-Activated Receptor-a and g in Apelin Action on the Kidney in Type 2 Diabetic Rat Model

  2020cites this paper
• Fenofibrate-induced renal dysfunction, yes or no?

  2020cites this paper
• Molecular targets of fenofibrate in the cardiovascular-renal axis: A unifying perspective of its pleiotropic benefits.

  2019cites this paper
• The safety profile of new antidiabetic xanthine derivatives and their chitosan based formulations

  2019cites this paper
• Nephroprotective effect of peroxisome proliferator-activated receptor-α and peroxisome proliferator-activated receptor-γ agonists on thioacetamide-induced nephrotoxicity in rats

  2019cites this paper
• Peroxisome proliferator-activated receptor-alpha agonists in the management of the diabetic acute kidney injury: Is the verdict out?

  2018cites this paper
• The signal pathway for the repressive effect of dipyridamole on myofibroblast transdifferentiation

  2018cites this paper
• Novel Anti-fibrotic Therapies

  2017cites this paper
• Effects of pre and post‐treatments with dipyridamole in gentamicin‐induced acute nephrotoxicity in the rat

  2017cites this paper
• Features of the pharmacological actions and the use of dipyridamole in the prevention and treatment of viral infections

  2016cites this paper
• Computational Drug Repositioning Using Continuous Self-Controlled Case Series

  2016cites this paper
• Effect of edaravone in diabetes mellitus-induced nephropathy in rats

  2016cites this paper
• Effect of Dipyridamole Injected for Myocardial Perfusion Imaging on Blood Glucose Concentration; A Preliminary Study.

  2016cites this paper
• Nephroprotective role of dipyridamole in diabetic nephropathy: Effect on inflammation and apoptosis.

  2015cites this paper
• Irbesartan can improve blood lipid and the kidney function of diabetic nephropathy.

  2015cites this paper
• Therapeutic Effects of PPARα on Neuronal Death and Microvascular Impairment

  2015cites this paper
• Механизмы нейротрофического и нейропротекторного действия препарата церебролизин при ишемии головного мозга

  2014cites this paper